[CAS NO. 173039-10-6] 2-PMPA
PRODUCTS SPECIFICATIONS [173039-10-6]
DESCRIPTION [173039-10-6]
Overview
| MDL | MFCD00940167 |
|---|---|
| Molecular Weight | 226.12 |
| Molecular Formula | C6H11O7P |
| SMILES | O=C(O)C(CP(O)(O)=O)CCC(O)=O |
4 Publications Citing Use of MCE
Summary
2-PMPA is a potent and selective inhibitor of glutamate carboxypeptidase II ( GCPII ) with an IC 50 of 300 pM.
IC50 & Target
IC50: 300 pM (GCPII) [1]
In Vitro
2-PMPA is a potent and selective inhibitor of GCPII, an enzyme which catabolizes the abundant neuropeptide N-acetyl-aspartyl-glutamate (NAAG) to N-acetylaspartate (NAA) and glutamate. 2-PMPA demonstrates robust efficacy in numerous animal models of neurological disease. 2-PMPA is a highly polar compound with multiple negative charges causing significant challenges for analysis in biological matrices [1] . 2-PMPA reduces ketamine-induced decrease of cell viability and increase of LDH levels in the mixed cultures but not in the neuronal cultures [2] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
In Vivo
Intraperitoneal administration of 100 mg/kg 2-PMPA results in maximum concentration in plasma of 275 μg/mL at 0.25 h. The half-life, area under the curve, apparent clearance, and volume of distribution are 0.64 h, 210 μg×h/mL, 7.93 mL/min/kg, and 0.44 L/kg, respectively [1] . 2-PMPA at 250 mg/kg, in an anesthetized mouse, after an initial rise, produces a rapid decline and a striking attenuation in BOLD signals in gray matter. The signature of 2-PMPA on brain T 2 * signals in gray matter at both 167 and 250 mg/kg includes a significant initial rise lasting several minutes [3] . 2-PMPA has neuroprotective activity in an animal model of stroke and anti-allodynic activity in CCI model. Administration of 2-PMPA (50mg/kg) produces a mean peak concentration of 2-PMPA of 29.66±8.1 μM. This concentration is about 100,000 fold more than is needed for inhibition of NAAG peptidase, and indicates very good penetration to the brain. Administration of 50 mg/kg 2-PMPA (i.p.) produces a continuously increasing extracellular NAAG concentration, which startes directly after application [4] .
MCE has not independently confirmed the accuracy of these methods. They are for reference only.
Appearance
Oil
Shipping
Room temperature in continental US; may vary elsewhere.
Storage
4°C, stored under nitrogen
* In solvent : -80°C, 6 months; -20°C, 1 month (stored under nitrogen)
Solvent & Solubility
H 2 O : ≥ 28 mg/mL ( 123.83 mM )
* "≥" means soluble, but saturation unknown.
Stock Solutions
| Concentration Solvent Mass | 1 mg | 5 mg | 10 mg |
|---|
| 1 mM | 4.4224 mL | 22.1122 mL | 44.2243 mL |
| 5 mM | 0.8845 mL | 4.4224 mL | 8.8449 mL |
| 10 mM | 0.4422 mL | 2.2112 mL | 4.4224 mL |
-
1.
Add each solvent one by one: PBS
Solubility: 100 mg/mL (442.24 mM); Clear solution; Need ultrasonic
References
- [1] Rais R, et al. Bioanalytical method for evaluating the pharmacokinetics of the GCP-II inhibitor 2-phosphonomethyl pentanedioic acid (2-PMPA). J Pharm Biomed Anal. 2014 Jan;88:162-9.
- [2] Zuo D, et al. Existence of glia mitigated ketamine-induced neurotoxicity in neuron-glia mixed cultures of neonatal rat cortex and the glia-mediated protective effect of 2-PMPA. Neurotoxicology. 2014 Sep;44:218-30.
- [3] Baslow MH, et al. 2-PMPA, a NAAG peptidase inhibitor, attenuates magnetic resonance BOLD signals in brain of anesthetized mice: evidence of a link between neuron NAAG release and hyperemia. J Mol Neurosci. 2005;26(1):1-15.
- [4] Nagel J, et al. Effects of NAAG peptidase inhibitor 2-PMPA in model chronic pain-relation to brain concentration. Neuropharmacology. 2006 Dec;51(7-8):1163-71.
Synonyms